Navigation Links
Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
Date:5/29/2012

CHADDS FORD, Pa., May 29, 2012 /PRNewswire/ -- Endo (Nasdaq: ENDP) announced today that it has reached an agreement with Watson Pharmaceuticals (Watson) resolving two patent infringement lawsuits related to LIDODERM (lidocaine patch 5%).  A trial was held on the first of these cases in February 2012, and this resolution was reached prior to the Judge issuing a decision in the case.

"We are pleased to have reached an agreement that protects Endo's intellectual property interests and eliminates the uncertainty of a court decision," said Dave Holveck, President and CEO of Endo.  "We believe this agreement will benefit consumers and resolving this issue is another step forward in establishing Endo as the dynamic, diversified healthcare solutions company that we are today." 

The settlement agreement outlines the terms of the agreement, which include:

  • Watson is unable to market a generic version of Lidoderm until the U.S. Food and Drug Administration (FDA) approves Watson's abbreviated new drug application (ANDA) for its lidocaine patch 5% product. 
  • If the FDA approves Watson's ANDA prior to September 15, 2013, Watson must wait until that day to market its generic product, except under certain limited circumstances. 
  • Endo will provide $12 million in branded Lidoderm product, based on wholesale acquisition cost, to Watson each month from January through August of 2013.
  • If the FDA does not approve Watson's ANDA by Dec. 31st, 2013, Endo will provide $6.67 million in branded Lidoderm product, based on wholesale acquisition cost, to Watson each month in 2014 that Watson's ANDA has not received FDA approval.
  • If the FDA does not approve Watson's ANDA by Dec. 31st, 2014, Endo will provide $7.11 million in branded Lidoderm product, based on wholesale acquisition cost, to
    '/>"/>

SOURCE Endo Health Solutions Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... FALLS, N.J. , May 1, 2015 CANTEL ... Andrew A. Krakauer , Chief Executive Officer, will be presenting ... at the Encore at the Wynn in Las ... Thursday, May 14, 2015 at 10:00 AM PT/1:00 PM ET. ... during the day. An audio webcast will ...
(Date:5/1/2015)... , May 1, 2015  Portal Instruments, Inc., ... delivery systems, announced today that Robert Langer, Sc. ... Ph.D., University of Auckland Distinguished Professor have joined the ... to welcome two esteemed biotechnology leaders, Professor Robert ... our team," said Dr. Patrick Anquetil , Chief ...
(Date:5/1/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world leader in ... hearts, announced today that Marta Antonucci has joined ... This new Europe -based position is ... North America , including Europe , ... , and reports directly to the Chief Executive Officer. Following ...
Breaking Medicine Technology:Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 2Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 3Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 4Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3
... 1, 2011 Milestone Scientific Inc. (OTCQB: MLSS), the ... the Company filed its 2010 year-end results for the ... Securities & Exchange Commission on Wednesday, March 30, 2011. ... teleconference Monday, April 4, 2011 beginning at 4:15 PM ...
... 2011 New data presented today at the 46th ... of the Liver (EASL) demonstrate the antiviral activity of ... both treatment-naive and -experienced patients with chronic genotype-1 (GT1) ... HCV to treat.  Results from SILEN-C1 show a sustained ...
Cached Medicine Technology:Milestone Scientific Will Host Its 2011 Conference Call on Monday, April 4, 2011 2Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 2Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 3Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 4Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 5Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 6
(Date:5/3/2015)... 03, 2015 SpineFrontier, a Less Exposure ... FDA to produce and market their new sacroiliac joint ... used in outpatient settings and is compatible with both ... approach has been extensively researched and refined by SpineFrontier, ... use this approach in conjunction with a sacroiliac joint ...
(Date:5/2/2015)... As one of only 30 Illinois companies ... Health Achievement and Recognition Program (SHARP) certification, Essentra ... the Illinois Department of Labor to host this special ... certification by the Occupational Safety and Health Administration’s (“OSHA”) ... to meet or exceed all of the necessary regulations ...
(Date:5/2/2015)... ” was featured on NewsWatch as part of its monthly ... applications on the market for iOS, Android, and Windows. Joe ... app review and shared with viewers how this app allows ... , In this material world, almost everything is about money. ... is why those things should be prioritized above others. And ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... May 02, 2015 Kare Visits LLC. launched ... for busy caregivers. Kare Visits offers relief for caregivers ... living facilities. According to the Caregiver Action Network, ... average of 20 hours a week caring for an elderly ... cost to hire a nurse, a caregiver is now empowered ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2
... AUGUSTA, Ga. A new strategy that takes advantage of ... extra months of life with few side effects, researchers say., ... a sort of front door by pairing a substance attracted ... be given systemically, said Dr. Sharad Ghamande, Chief of the ...
... BOSTON -- Even yeast understand austerity. A finely tuned system evolved ... times come as fast as they go. The system, a molecular ... protein that turns growth on in times of plenty and shuts ... lab of Wenyi Wei, PhD, an investigator in the Department of ...
... Reporter , THURSDAY, Oct. 27 (HealthDay News) -- Two aspirin a ... half in people who are predisposed to these types of tumors, ... each also cut the risk of other tumors related to Lynch ... to research published in the Oct. 28 online edition of ...
... Reinberg HealthDay Reporter , THURSDAY, Oct. 27 (HealthDay ... part B benefits in 2012 will be less than expected ... U.S. health officials said Thursday. However, for those already ... most people with Medicare have paid a monthly premium of ...
... fourth-generation oncolytic virus designed to both kill cancer cells ... earlier versions when tested in animal models of human ... University Comprehensive Cancer Center Arthur G. James Cancer ... James) are developing the oncolytic virus as a treatment ...
... 27, 2011Bruce Beutler, MD, a co-recipient of the 2011 Nobel ... molecular mechanism that can cause the body to attack itself ... ahead of print in Journal of Interferon & Cytokine ... Inc. ( www.liebertpub.com ) and is available free at ...
Cached Medicine News:Health News:Folate receptors may serve as a front door to ovarian cancer treatment 2Health News:Unraveling the complex signaling that helps cells know when to grow, when to sit tight 2Health News:Unraveling the complex signaling that helps cells know when to grow, when to sit tight 3Health News:Daily Aspirin May Help Prevent Colon Cancer for Those at High Risk 2Health News:Daily Aspirin May Help Prevent Colon Cancer for Those at High Risk 3Health News:Medicare Part B Premium Increase Lower Than Expected 2Health News:New oncolytic virus shows improved effectiveness in preclinical testing 2
... information to facilitate diagnostic accuracy for appropriate ... sterile, disposable device used to inject fluid ... procedures. The device will measure the pressure ... a digital format. The physician can control ...
Maxi-Therm® hyper-hypothermia water blankets from Cincinnati Sub-Zero are designed for single-patient use. These blankets are easy to clean, stain resistant and ideal for isolation cases....
The Neuro-Cool™ System provides pain relief by combining a head wrap with a cold therapy unit for effective migraine treatment....
The ImmunoWELL Borrelia M Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi,IgM antibodies in serum and is used as an aid in the diag...
Medicine Products: